Pulmonary Circulation, 2022 Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States.
Sandeep Sahay +2 more
exaly +2 more sources
Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report [PDF]
Clinical Case ReportsThe optimal approach to transitioning from oral treprostinil to intravenous treprostinil in pulmonary arterial hypertension (PAH) has been poorly characterized in published literature.
Abigail M. Cummings +3 more
doaj +2 more sources
The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification [PDF]
Clinical and Translational Science, Volume 19, Issue 8, August 2026.ABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Surya Ayalasomayajula +8 more
wiley +2 more sources
Pulmonary Veno‐Occlusive Disease: A Focused Clinicopathologic Series [PDF]
Pulmonary Circulation, Volume 16, Issue 3, July 2026.ABSTRACT Pulmonary veno‐occlusive disease (PVOD) is a rare and aggressive subtype of pulmonary arterial hypertension characterized by fibroproliferative obstruction of post‐capillary pulmonary venules leading to increased pulmonary vascular resistance and progressive right ventricular failure.
Yub Raj Sedhai +12 more
wiley +2 more sources
Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
Pulmonary Circulation, 2019 Treprostinil, a prostacyclin analogue, is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Transition from parenteral to oral treprostinil has been successfully accomplished in adults with PAH but not in children.
Mary Mullen +2 more
exaly +2 more sources
Parenteral treprostinil in paediatric pulmonary arterial hypertension: a systematic review and meta-analysis [PDF]
European Respiratory ReviewBackground Paediatric pulmonary arterial hypertension (PAH) shares commonalities with adult disease but is essentially different regarding complexity and is usually more challenging to treat. Current treatment recommendations are based on expert opinion,
Julie Wacker +2 more
doaj +2 more sources
The differential effects of cAMP mobilizing agents on TGF-β-induced extracellular matrix in human lung-derived fibroblasts: insights into therapeutic targets for lung fibrosis [PDF]
Respiratory ResearchBackground Injury-repair responses typically induce tissue or organ scarring. Generally, cAMP-mobilizing agents inhibit the activation of fibroblasts and deposition of extracellular matrix.
Sarah Orfanos +8 more
doaj +2 more sources
Therapeutic Advances in Respiratory Disease, 2018 Treprostinil diolamine is the first oral prostacyclin approved for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity.
Taylor J Miller, James C Coons
exaly +2 more sources
Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases [PDF]
JA Clinical ReportsBackground Treprostinil, a prostacyclin analogue, is an effective treatment for pulmonary arterial hypertension (PAH). However, continuous subcutaneous infusion is often complicated by severe injection site pain, which can limit continuation of therapy ...
Shuji Kawamoto +7 more
doaj +2 more sources
Pulmonary Circulation, 2023 Treprostinil is a prostacyclin analogue that targets multiple cellular receptors to treat pulmonary arterial hypertension (PAH). In certain scenarios, patients may require aggressive treprostinil titration.
John F. Kingrey +15 more
doaj +1 more source